Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (retinal pigment epithelial cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 54 | 0.91 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 16661
Sealed predictions
- SLC6A13 in dopamine neurons, braak-0.22 (p 0.563) → +0.08 (p 0.840)receipt 16669
Swarm cases
receipt 16669: SLC6A13 in dopamine neurons, braak
- power
- full sample -0.22 (p 0.389, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.18 (p 0.471, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.40 (p 0.103, n 18). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.12, sign flips 0; without severely affected donors -0.22 (p 0.389, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC6A13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts